RxDoctor Payments Data

Meesun Sim, MD

Internal Medicine · Plano, TXNPI 1205018926

Payments from drug & device makers

$3,972in general payments, 2019–2025

Across 164 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$775
  • Amarin Pharma, Inc.$344
  • Lilly USA, LLC$332
  • Merck$250
  • Boehringer Ingelheim$229
  • plus $936 from 16 others

What the payments were for

  • Food & beverage$3,82696%
  • Education$1464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,972 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,532
Medicare patients
72
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$73,918
FarxigaDapagliflozin Propanediol35$47,942
JanuviaSitagliptin Phosphate22$36,377
VascepaIcosapent Ethyl28$25,362
JardianceEmpagliflozin25$22,842
TradjentaLinagliptin14$18,807
MounjaroTirzepatide14$16,154
Omega-3 Acid Ethyl Esters16$3,656
Memantine Hcl ErMemantine Hcl16$3,355
Atorvastatin Calcium404$3,032
Rosuvastatin Calcium260$2,129
Amlodipine Besylate256$1,605
Tamsulosin Hcl104$1,287
Losartan Potassium165$1,229
Ezetimibe89$1,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$73,91843 claims
AstraZenecaFarxiga$1,107$47,94235 claims
Boehringer IngelheimJardiance, Tradjenta$229$41,64839 claims
MerckJanuvia$250$36,37722 claims
Lilly USA, LLCMounjaro$332$16,15414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →